sam® by Zetroz Systems uses high-frequency, low-intensity continuous ultrasound to facilitate healing of injured musculoskeletal tissue in the patient’s home.
sam® 2.0 is available for home use to treat common soft tissue injuries
TRUMBULL, Conn., Jul. 28, 2022 (GLOBE NEWSWIRE) — According to a recently published review of medical research, sustained acoustic medicine (SAM) delivered by Zetroz Systems’ sam® device is effective in healing soft tissue injuries, restoring functioning in patients and helping them return to work or other normal daily activities.
The study, published in the journal BMC Sports Science, Medicine and Rehabilitationis a systematic review and meta-analysis to analyze the effects of SAM treatment on musculoskeletal injuries, including diathermy (tissue heating), functional outcomes (strength and range of motion), quality of life, pain reduction, and intervention safety profile.
The authors reviewed 13 previously published studies involving 372 patients. “Continued treatment with acoustic medicine provides tissue heating and tissue repair, improved patient function and reduction of pain,” the authors found. “When patients failed to respond to physical therapy, Sustained Acoustic Medicine proved to be a useful adjunct to facilitate healing and return to work. As a non-invasive and non-narcotic treatment option with an excellent safety profile, Sustained Acoustic Medicine may be considered a good therapeutic option for practitioners.”
The study also concluded that sam® performs the following functions:
Accelerates return to function and performance: When patients failed to respond to traditional therapies (RICE), 87% experienced an improvement in function and quality of life, and 55% were able to return to activity immediately after treatment.
Provides a safe and strong diathermic effect. The patient’s target tissue experienced a significant change in therapeutic heat, increasing from 4°C to 12°C, while maintaining a safe temperature on the skin.
Reduces lactic acid and improves muscle and joint performance: Patients saw a 20% reduction in blood lactate, a 27 to 87 percent improvement in joint function, and more strength, work and torque.
Heals while reducing pain: Long-term, low-intensity ultrasound such as sam® treatment increases vasodilation (blood flow and oxygenation), which elongates the collagen fiber matrix, accelerates healing and increases the integrity of injured soft tissue, significantly alleviating patient pain reduced.
Easy to integrate into the patient’s self-care regimen at home: 95% of patients were able to apply and perform the sam® treatment, and 93% of patients found sam® to be very user-friendly.
“This new study supports what we know from years of research and development and patient experience,” said George K. Lewis, Ph.D., and CEO of ZetrOZ Systems. “We hope that long-term acoustic medicine is widely adopted by physicians and healthcare providers to help even more people heal soft tissue, reduce pain and return them to normal daily activities even faster.”
The researchers’ summary agrees, suggesting doctors are considering wider adoption of SAM. “The data presented in these clinical trials demonstrate a positive and significant benefit for patients,” they wrote. In addition, recent health economics and SAM research analyzes support the acceptance of medical guidelines for SAM as a new mechanobiological treatment for patient care. SAM treatment, which is widely used in sports medicine, can be more broadly regarded as a non-invasive, safe and effective treatment option. for patients with musculoskeletal pain and soft tissue injuries.”
For more information about ZetrOZ Systems and its innovative health solutions, please visit www.zetroz.com.
About ZestrOZ Systems
ZetroZ Systems is an FDA cGMP and ISO 13585 medical technology company headquartered in the southern coastal region of Connecticut. The organization also has manufacturing facilities in the United States. ZetrOZ Systems manufactures UltrOZ®, sam®Sport and sam®Pro 2.0 to provide safe and effective treatment options for common conditions such as arthritis. Learn more at zetroz.com and samrecover.com.
Figure 1: sam® 2.0 is available for home use to treat common soft tissue injuries
This content is published through the press release distribution service at Newswire.com.